Type 2 Inflammation - Severe Asthma and Co-Morbidities
Price: FREE for members and non-members
Session recorded on July 23, 2019
Speaker: Bradley, Chipps, MD
Viewers can earn credit by completing the post test questions.
This activity aims to provide both the appropriate background information and the prescribing guidance based in published clinical evidence, required to improve the competence of learner's ability to choose the best medical therapy for patients with Type 2 Inflammation.
This program is a collaboration between the American College of Allergy, Asthma and Immunology and the Allergy and Asthma Network.
There is no commercial support for this activity.
Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Target Audience
Primary Care Providers
Learning Objectives
After viewing the video recording learners should be able to:
- Determine the response predictors for the 5 monoclonal antibodies for asthma
- Examine the specific criteria for monoclonal antibodies
- Explore the limited intervention for low T2 asthma
Accreditation
The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation
The American College of Allergy, Asthma and Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance